Literature DB >> 17199558

Immunopathogenesis in hepatitis C virus cirrhosis.

Ulrich Spengler1, Jacob Nattermann.   

Abstract

HCV (hepatitis C virus) has a high propensity to persist and to cause chronic hepatitis C, eventually leading to cirrhosis. Since HCV itself is not cytopathic, liver damage in chronic hepatitis C is commonly attributed to immune-mediated mechanisms. HCV proteins interact with several pathways in the host's immune response and disrupt pathogen-associated pattern recognition pathways, interfere with cellular immunoregulation via CD81 binding and subvert the activity of NK (natural killer) cells as well as CD4(+) and CD8(+) T-cells. Finally, HCV-specific T-cells become increasingly unresponsive and apparently disappear, owing to several possible mechanisms, such as escape mutations in critical viral epitopes, lack of sufficient help, clonal anergy or expansion of regulatory T-cells. The role of neutralizing antibodies remains uncertain, although it is still possible that humoral immunity contributes to bystander damage of virally coated cells via antibody-dependent cellular cytotoxicity. Cytotoxic lymphocytes kill HCV-infected cells via the perforin/granzyme pathway, but also release Fas ligand and inflammatory cytokines such as IFNgamma (interferon gamma). Release of soluble effector molecules helps to control HCV infection, but may also destroy uninfected liver cells and can attract further lymphocytes without HCV specificity to invade the liver. Bystander damage of these non-specific inflammatory cells will expand the tissue damage triggered by HCV infection and ultimately activate fibrogenesis. A clear understanding of these processes will eventually help to develop novel treatment strategies for HCV liver disease, independent from direct inhibition of HCV replication.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17199558     DOI: 10.1042/CS20060171

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  31 in total

1.  Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis.

Authors:  Miroslaw Kornek; Michael Lynch; Shruti H Mehta; Michelle Lai; Mark Exley; Nezam H Afdhal; Detlef Schuppan
Journal:  Gastroenterology       Date:  2012-04-24       Impact factor: 22.682

Review 2.  Macrophages in hepatitis B and hepatitis C virus infections.

Authors:  Mathis Heydtmann
Journal:  J Virol       Date:  2008-10-08       Impact factor: 5.103

3.  Extra-hepatic infection of hepatitis C virus in the colon tissue and its relationship with hepatitis C virus pathogenesis.

Authors:  Helal F Hetta; Mohamed A Mekky; Nasr K Khalil; Wegdan A Mohamed; Mohamed A El-Feky; Shabaan H Ahmed; Enas A Daef; Ahmed Medhat; Mahmoud I Nassar; Kenneth E Sherman; Mohamed Tarek M Shata
Journal:  J Med Microbiol       Date:  2016-05-10       Impact factor: 2.472

Review 4.  Viral hepatitis in elderly haemodialysis patients: current prevention and management strategies.

Authors:  Matthias Girndt
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 5.  Immunomodulatory effects of transforming growth factor-β in the liver.

Authors:  Hans-Theo Schon; Ralf Weiskirchen
Journal:  Hepatobiliary Surg Nutr       Date:  2014-12       Impact factor: 7.293

Review 6.  The role of chemokines in acute and chronic hepatitis C infection.

Authors:  Stephen Fahey; Eugene Dempsey; Aideen Long
Journal:  Cell Mol Immunol       Date:  2013-08-19       Impact factor: 11.530

7.  Ribavirin modulates the conversion of human CD4(+)  CD25(-) T cell to CD4(+)  CD25(+)  FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell.

Authors:  Tamaki Kobayashi; Katsuhisa Nakatsuka; Masumi Shimizu; Hideto Tamura; Eiji Shinya; Masanori Atsukawa; Hirotomo Harimoto; Hidemi Takahashi; Choitsu Sakamoto
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

Review 8.  Chemokines in the immunopathogenesis of hepatitis C infection.

Authors:  Mathis Heydtmann; David H Adams
Journal:  Hepatology       Date:  2009-02       Impact factor: 17.425

9.  Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection.

Authors:  Chihiro Morishima; Margaret C Shuhart; Chia C Wang; Denise M Paschal; Minjun C Apodaca; Yanze Liu; Derek D Sloan; Tyler N Graf; Nicholas H Oberlies; David Y-W Lee; Keith R Jerome; Stephen J Polyak
Journal:  Gastroenterology       Date:  2009-09-24       Impact factor: 22.682

10.  Accumulation of platelets in the liver may be an important contributory factor to thrombocytopenia and liver fibrosis in chronic hepatitis C.

Authors:  Reiichiro Kondo; Hirohisa Yano; Osamu Nakashima; Ken Tanikawa; Yoriko Nomura; Masayoshi Kage
Journal:  J Gastroenterol       Date:  2012-08-22       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.